ABSTRACT
BACKGROUND AND OBJECTIVES: To evaluate the potential benefits of Bacteroides fragilis 839 (BF839), a next-generation probiotics, in reducing myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patient. METHODS AND STUDY DESIGN: 40 women with early breast cancer were randomly assigned to the BF839 (n=20) or placebo (n=20) during the administration of adjuvant chemotherapy (4 cycles of epirubicin 100mg/m2 and cyclophosphamide 600mg/m2). Myelosuppression and gastrointestinal adverse effects were monitored in both groups. RESULTS: Throughout the four treatment cycles, the percentage of patients experiencing myelosuppression was 42.5% in the BF839 group, significantly lower than the 66.3% observed in the control group (p=0.003). Two patients in the BF839 group and three patients in the placebo group received recombinant human granulocyte colony-stimulating factor (rhG-CSF) due to leuko-penia/neutropenia. When considering an ITT analysis, which included all patients regardless of rhG-CSF treatment, the BF839 group exhibited less reduction from baseline in white blood cells (-0.31±1.19 vs -1.15±0.77, p=0.012) and neutrophils (0.06±1.00 vs -0.84±0.85, p=0.004) compared to the placebo group. The difference became even more significant when excluding the patients who received rhG-CSF injections. Throughout the four treatment cycles, compared to the placebo group, the BF839 group had significantly lower rates of 3-4 grade nausea (35.0% vs 71.3%, p=0.001), vomiting (20.0% vs 45.0%, p=0.001), and diarrhea (15.0% vs 30.0%, p=0.023). CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.
Subject(s)
Antineoplastic Agents , Breast Neoplasms , Female , Humans , Antineoplastic Agents/adverse effects , Bacteroides fragilis , Breast Neoplasms/drug therapy , Cyclophosphamide/adverse effects , Epirubicin/adverse effects , Granulocyte Colony-Stimulating Factor/therapeutic use , Recombinant Proteins/therapeutic useABSTRACT
The accuracy and sensitivity of prostate-specific antigen (PSA) for prostate cancer diagnosis is often poor; however, the reasons for its inaccuracy have rarely been investigated, especially with respect to age. In this study, 476 healthy males, aged 10-89 years, were stratified into eight age groups, and levels of seven markers were determined: total PSA (tPSA), free PSA (fPSA), %fPSA, isoform [-2]proPSA (p2PSA), p2PSA/tPSA, %p2PSA, and the prostate health index (PHI). Both tPSA and fPSA levels increased with age. The tPSA level was highest (1.39 ng ml-1) at 70-79 years; %fPSA was highest (0.57 ng ml-1) at 10-19 years; and %p2PSA was lowest (18.33 ng ml-1) at 40-49 years. Both p2PSA and p2PSA/tPSA had relatively flat curves and showed no correlation with age (P = 0.222). PHI was a sensitive age-associated marker (P < 0.05), with two peaks and one trough. The coverage rates and radiance graphs of PHI and %p2PSA were more distinctive than those of tPSA and the other markers. In subjects older than 69 years, PHI and %p2PSA both began to decrease, approximately 10 years earlier than the decrease in tPSA. Our results suggest that the clinical diagnosis of prostate cancer using PSA should be investigated more comprehensively based on patient age. Moreover, %p2PSA and PHI could be considered as earlier markers that may be more suitable than PSA alone.
Subject(s)
Biomarkers, Tumor/analysis , Prostatic Neoplasms/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Asian People , Child , China/epidemiology , Cohort Studies , Health Status , Humans , Male , Middle Aged , Prospective Studies , Prostate/physiopathology , Prostate-Specific Antigen/analysis , Risk Assessment , Young AdultABSTRACT
Due to the high morbidity, mortality and late detection of hepatocellular carcinoma (HCC), it becomes a major public health challenge. MicroRNAs (miRNAs) have been reported to be aberrantly expressed in patients with HCC and thus may serve as potential diagnostic biomarkers. The aim of this study was to systematically assess the diagnostic accuracy of miRNAs as biomarkers for diagnosing HCC through a meta-analysis. Our results indicated that serum miRNAs had a relatively high diagnostic value for HCC diagnosis; the combination of serum α-fetoprotein (AFP) and miRNAs displayed a better diagnostic accuracy than using AFP or miRNAs alone; the combination of multiple miRNAs assay in serum had the highest diagnostic accuracy in HCC diagnosis based on the published data. In conclusion, our meta-analysis suggests that miRNAs, especially serum miRNAs, had a relatively high diagnostic value for HCC diagnosis, which can discriminate HCC from healthy subjects and those with chronic hepatitis and cirrhosis easily, and may serve as a novel, less-invasive screening tool.
Subject(s)
Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , MicroRNAs/blood , Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/blood , Humans , Liver Neoplasms/blood , alpha-Fetoproteins/analysisABSTRACT
BACKGROUND: Parkinson's disease (PD) is a common neurodegenerative disease affecting the quality of life in the elderly. We speculated that PD patients might have abnormal pharmacodynamics due to the degenerative neural system, and the present study was performed to investigate the pharmacodynamics of remifentanil in PD patients. MATERIALS AND METHODS: Two arms of patients were recruited, including 31 PD patients undergoing pulse generator placement after deep brain stimulator implantation and 31 pair-controlled patients undergoing intracranial surgery without PD (NPD). Patients were anesthetized with target-controlled infusion of propofol and remifentanil. The effective concentration of remifentanil to inhibit responses to intubation and skin incision in 50% and 95% patients (EC50 and EC95) was determined by the up and down method. RESULTS: Demographic data, bispectral index, and hemodynamic values were similar between the PD and the NPD groups. The average remifentanil concentration used in the PD group for tracheal intubation is significantly lower than in the NPD group (P<0.001). The EC50 for inhibiting the response to tracheal intubation were 1.86 ng/mL (95% confidential interval [CI], 1.77-1.96 ng/mL) in the PD group and 3.20 ng/mL (95% CI, 3.13-3.27 ng/mL) in the NPD group. The average remifentanil concentration used in the PD group for skin incision is significantly lower than in the NPD group (P<0.001). EC50 for inhibiting the response to skin incision were 2.17 ng/mL (95% CI, 2.09-2.25 ng/mL) in the PD group and 3.09 ng/mL (95% CI, 3.02-3.17 ng/mL) in the NPD group. CONCLUSIONS: The remifentanil concentrations required for inhibiting responses to tracheal intubation and skin incision are reduced markedly in PD patients undergoing pulse generator placement (NCT01992692).
Subject(s)
Anesthetics, Intravenous/pharmacology , Deep Brain Stimulation/instrumentation , Intubation, Intratracheal , Parkinson Disease/surgery , Piperidines/pharmacology , Surgical Wound , Female , Humans , Male , Middle Aged , Prospective Studies , Remifentanil , SkinABSTRACT
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, but whether the neurodegenerative process influences the pharmacodynamics of propofol remains unclear. We aimed to evaluate the effect of PD on pharmacodynamics of propofol. A total of 31 PD patients undergoing surgical treatment (PD group) and 31 pair-controlled non-PD patients undergoing intracranial surgery (NPD group) were recruited to investigate the propofol requirement for unconsciousness induction. Unconsciousness was induced in all patients with target-controlled infusion of propofol. The propofol concentration at which unconsciousness was induced was compared between the two groups. EC50 and EC95 were calculated as well. Demographic data, bispectral index, and hemodynamic values were comparable between PD and NPD groups. The mean target concentration of propofol when unconsciousness was achieved was 2.32 ± 0.38 µg/mL in PD group, which was significantly lower than that in NPD group (2.90 ± 0.35 µg/mL). The EC50 was 2.05 µg/mL (95% CI: 1.85-2.19 µg/mL) in PD group, much lower than the 2.72 µg/mL (95% CI: 2.53-2.88 µg/mL) in NPD group. In conclusion, the effective propofol concentration needed for induction of unconsciousness in 50% of patients is reduced in PD patients. (This trial is registered with NCT01998204.).
Subject(s)
Consciousness/drug effects , Drug Administration Schedule , Propofol/administration & dosage , Anesthetics, General/administration & dosage , Case-Control Studies , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Parkinson Disease/physiopathology , Treatment OutcomeABSTRACT
AIM: To characterize the pharmacological profiles of a novel κ-opioid receptor agonist MB-1C-OH. METHODS: [(3)H]diprenorphine binding and [(35)S]GTPγS binding assays were performed to determine the agonistic properties of MB-1C-OH. Hot plate, tail flick, acetic acid-induced writhing, and formalin tests were conducted in mice to evaluate the antinociceptive actions. Forced swimming and rotarod tests of mice were used to assess the sedation and depression actions. RESULTS: In [(3)H]diprenorphine binding assay, MB-1C-OH did not bind to µ- and δ-opioid receptors at the concentration of 100 µmol/L, but showed a high affinity for κ-opioid receptor (Ki=35 nmol/L). In [(35)S]GTPγS binding assay, the compound had an Emax of 98% and an EC50 of 16.7 nmol/L for κ-opioid receptor. Subcutaneous injection of MB-1C-OH had no effects in both hot plate and tail flick tests, but produced potent antinociception in the acetic acid-induced writhing test (ED50=0.39 mg/kg), which was antagonized by pretreatment with a selective κ-opioid receptor antagonist Nor-BNI. In the formalin test, subcutaneous injection of MB-1C-OH did not affect the flinching behavior in the first phase, but significantly inhibited that in the second phase (ED50=0.87 mg/kg). In addition, the sedation or depression actions of MB-1C-OH were about 3-fold weaker than those of the classical κ agonist (-)U50,488H. CONCLUSION: MB-1C-OH is a novel κ-opioid receptor agonist that produces potent antinociception causing less sedation and depression.
Subject(s)
Analgesics, Opioid/pharmacology , Behavior, Animal/drug effects , Isoquinolines/pharmacology , Pain Threshold/drug effects , Pain/prevention & control , Receptors, Opioid, kappa/agonists , Wakefulness/drug effects , Analgesics, Opioid/metabolism , Analgesics, Opioid/toxicity , Animals , Binding, Competitive , CHO Cells , Cricetulus , Depression/chemically induced , Depression/metabolism , Depression/psychology , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Isoquinolines/metabolism , Ligands , Male , Mice , Motor Activity/drug effects , Pain/metabolism , Pain/physiopathology , Pain/psychology , Protein Binding , Rats , Receptors, Opioid, kappa/genetics , Receptors, Opioid, kappa/metabolism , TransfectionABSTRACT
Deep brain stimulation (DBS) is an effective technique for treating Parkinson's disease (PD) in the middle and advanced stages. The subthalamic nucleus (STN) is the most common target for clinical treatment using DBS. While STN-DBS can significantly improve motor symptoms in PD patients, adverse cognitive effects have also been reported. The specific effects of STN-DBS on cognitive function and the related mechanisms remain unclear. Thus, it is imperative to identify the influence of STN-DBS on cognition and investigate the potential mechanisms to provide a clearer view of the various cognitive sequelae in PD patients. For this review, a literature search was performed using the following inclusion criteria: (1) at least 10 patients followed for a mean of at least 6 months after surgery since the year 2006; (2) pre- and postoperative cognitive data using at least one standardized neuropsychological scale; and (3) adequate reporting of study results using means and standard deviations. Of â¼170 clinical studies identified, 25 cohort studies (including 15 self-controlled studies, nine intergroup controlled studies, and one multi-center, randomized control experiment) and one meta-analysis were eligible for inclusion. The results suggest that the precise mechanism of the changes in cognitive function after STN-DBS remains obscure, but STN-DBS certainly has effects on cognition. In particular, a progressive decrease in verbal fluency after STN-DBS is consistently reported and although executive function is unchanged in the intermediate stage postoperatively, it tends to decline in the early and later stages. However, these changes do not affect the improvements in quality of life. STN-DBS seems to be safe with respect to cognitive effects in carefully-selected patients during a follow-up period from 6 months to 9 years.
Subject(s)
Cognition/physiology , Deep Brain Stimulation , Parkinson Disease/psychology , Parkinson Disease/therapy , Subthalamic Nucleus/physiopathology , Executive Function/physiology , HumansABSTRACT
Angiocentric glioma (AG) was recognized as a distinct clinicopathological tumor in 2007, but it is rarely reported. We report a patient with AG who presented with dizziness, and whose MRI images revealed a circumscribed lesion with heterogeneous contrast enhancement and evidence of previous bleeding. Thirty-three patients with AG have been reported to date. Most AG patients present with intractable seizures, usually in childhood and as young adults. However, the presentations reported are diverse, therefore the final diagnosis of AG should depend on the histopathological examination.
Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/surgery , Glioma/diagnosis , Glioma/surgery , Neovascularization, Pathologic/diagnosis , Neovascularization, Pathologic/surgery , Brain Neoplasms/physiopathology , Glioma/physiopathology , Humans , Male , Neovascularization, Pathologic/physiopathology , Young AdultABSTRACT
OBJECTIVE: To investigate the influence of high frequency stimulation of the subthalamic nucleus on the levels of amino acids neurotransmitters in striatum of hemi-parkinsonian monkeys. METHODS: Two rhesus monkeys were successfully prepared for the subsequent microdialysis sessions. Collecting the dialysate before turning on the pulse generator, and collecting at 1 week, 1, 8 and 12 months after high frequency stimulation of the subthalamic nucleus. The level of Glu, GABA and Tau were determined by high performance liquid chromatography and fluorometric detection (HPLC-FD). RESULTS: After high frequency stimulation (HFS), PD symptoms of monkeys significantly improved. The levels of Glu in putamen and caudate nucleus of electrodes side at 1 week, 1, 8 and 12 months were increased significantly. The levels of GABA in putamen and caudate nucleus of electrodes side at 1 week, 1 month increased significantly compared with before turning on the pulse generator while decreased at 8, 12 months. The level of Tau in putamen and caudate nucleus increased significantly. CONCLUSION: Long-term STN HFS can increase the level of glutamate and taurine, while decrease the level of GABA in putamen and caudate nucleus of electrodes side. It improves symptoms of hemi-parkinsonian rhesus monkey significantly.